Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a Comment »
The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being [...]
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: blood clots, Capesaris, complications, GTx-758, risk | Leave a Comment »
Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer?
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ipilimumab, TAK-700, tasquinimod, trials | Leave a Comment »
It has been suggested that, after an initial “loading dose” for a period of time, abiraterone acetate could potentially be used to treat metastatic, castration-resistant prostate cancer (mCRPC) at a much lower daily maintenance dose than that currently approved.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, low-dose, maintenance | 10 Comments »
We promised to give a summary of other interesting prostate cancer-related data presented at the Genitourinary Cancer Symposium out in San Francisco. Here is an an initial commentary on some of the presentations that seemed (to us) to be of particular interest:
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | 3 Comments »
One of the most useful elements introduced this year at the Genitourinary Cancer Symposium still ongoing in San Francisco is the summary papers from the educational reviews presented at the meeting.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Leave a Comment »
According to a number of media reports today, Medivation’s investigational drug MDV3100 appears to have a relatively good safety profile, although five patients who received MDV3100 in the completed Phase III trial did have seizures.
Filed under: Drugs in development, Management, Treatment | Tagged: efficacy, mCRPC, MDV3100, Phase III, safety | 5 Comments »
The full meeting agenda and abstracts for the upcoming Genitourinary Cancers Symposium (co-sponsored by ASCO and others) are now available on line. The prostate cancer session will start tomorrow morning in San Francisco; unfortunately we have not been able to send a reporter to this meeting this year.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | 1 Comment »
The January 2012 issue of Oncology contains an open access, full-text article on the future sequencing of the recently approved and potentially new drugs that are or should soon be available for the treatment of advanced prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, drugs, new, sequencing | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site